NeuroXess
PrivateLast Round
Series B
Oct 28, 2026
Total Funding Raised
$110.2M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
NeuroXess operates in Healthcare & Life Sciences and is based in Shanghai. Its latest recorded funding round was a Series B round in October 2026.
NeuroXess is a life sciences company that develops implantable, wireless brain-computer interface (BCI) systems, including flexible electrodes and decoding software, to assist patients with neurological disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Medical Devices, Medical AI, Clinical Trials, Health IoT
Business Model
B2B
Customer Profile
Hardware Sales, Subscription SaaS
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
NeuroXess Comparables
Compare NeuroXess with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Shanghai StairMed Technology Co., Ltd. | 87% | |
| Axoft | 85% | |
| Neuracle | 83% |
For institutional investors. Book with your work email.
NeuroXess Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Oct 28, 2026 | ||||
| Series A Extension | Jul 7, 2026 | ||||
| Series A | Dec 28, 2022 | ||||
| Seed | Jan 11, 2022 |
For institutional investors. Book with your work email.
NeuroXess Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| New Alliance Capital | Series A, Seed |
| IDG Capital | Series B |
| Shanghai Guosheng Capital Management Co., Ltd. | Series A |
| Shanghai Sailing Capital | Series A |
| Morningstar Ventures | Series B |
| Triwise Capital | Series B |
| Zhongping Capital | Series B, Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 28, 2026
Completed a Series B funding round.
- Aug 1, 2026
Open roles increased to 36, 720% of headcount.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_financingOct 28, 2026
NeuroXess receives $105M in Series B financing in China to advance its “Three-Comprehensive” brain-computer interface into registration clinical trials on Oct 28th '26.
For institutional investors. Book with your work email.
NeuroXess Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about NeuroXess's valuation, stock price, and market status.
Is NeuroXess a public or private company?
NeuroXess is a private company.
What is the current stock price of NeuroXess?
NeuroXess is a private company, so its shares have no public market price. Caplight tracks NeuroXess's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is NeuroXess worth (valuation)?
Valuation information for NeuroXess is not publicly available.
Can I buy NeuroXess stock?
NeuroXess shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was NeuroXess's last funding round?
NeuroXess's most recent funding round was Series B on October 28, 2026.
Who are the main investors in NeuroXess?
Key investors in NeuroXess include Zhongping Capital, Sequoia Capital, Shanda Capital, 国投聚力投资管理有限公司, Shenzhen Capital Group.
Will NeuroXess IPO soon?
No public IPO plans have been announced for NeuroXess.
How can I track NeuroXess secondary market activity?
Caplight tracks bids, offers, and trades in NeuroXess's shares on secondary markets.